Alkermes plc Stock News

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Does Alkermes (ALKS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephriti

Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.

Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by th

Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.